Literature DB >> 30120060

T Cell Tumor Immunotherapy: Oncolysis Beats Lymphodepletion.

John Barrett1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30120060      PMCID： PMC6127678          DOI： 10.1016/j.ymthe.2018.08.004

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  11 in total

Review 1.  Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

Authors:  Christopher A Klebanoff; Hung T Khong; Paul A Antony; Douglas C Palmer; Nicholas P Restifo
Journal:  Trends Immunol       Date:  2005-02       Impact factor: 16.687

2.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

3.  Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.

Authors:  Siri Tähtinen; Susanna Grönberg-Vähä-Koskela; Dave Lumen; Maiju Merisalo-Soikkeli; Mikko Siurala; Anu J Airaksinen; Markus Vähä-Koskela; Akseli Hemminki
Journal:  Cancer Immunol Res       Date:  2015-05-14       Impact factor: 11.151

Review 4.  Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.

Authors:  Vincenzo Cerullo; Anniina Koski; Markus Vähä-Koskela; Akseli Hemminki
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

5.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

6.  Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity.

Authors:  T Guillaume; B Gaugler; P Chevallier; J Delaunay; S Ayari; A Clavert; F Rialland; S Le Gouill; N Blin; T Gastinne; B Mahé; V Dubruille; P Moreau; M Mohty
Journal:  Bone Marrow Transplant       Date:  2011-11-28       Impact factor: 5.483

Review 7.  CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.

Authors:  Alexandra S Onea; Ali R Jazirehi
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

8.  Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.

Authors:  Catherine M Bollard; Stephen Gottschalk; Vicky Torrano; Oumar Diouf; Stephanie Ku; Yasmin Hazrat; George Carrum; Carlos Ramos; Luis Fayad; Elizabeth J Shpall; Barbara Pro; Hao Liu; Meng-Fen Wu; Daniel Lee; Andrea M Sheehan; Youli Zu; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Clin Oncol       Date:  2013-12-16       Impact factor: 44.544

9.  Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.

Authors:  João Manuel Santos; Víctor Cervera-Carrascon; Riikka Havunen; Sadia Zafar; Mikko Siurala; Suvi Sorsa; Marjukka Anttila; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2018-07-13       Impact factor: 11.454

10.  Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.

Authors:  Riikka Havunen; Mikko Siurala; Suvi Sorsa; Susanna Grönberg-Vähä-Koskela; Michael Behr; Siri Tähtinen; João Manuel Santos; Pauliina Karell; Juuso Rusanen; Dirk M Nettelbeck; Anja Ehrhardt; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther Oncolytics       Date:  2016-12-31       Impact factor: 7.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.